Migraines are estimated to affect 10% to 29% of women during the menopause transition, when migraines often worsen and become more frequent, especially during perimenopause. This is due to unpredictable estrogen drops. A new study suggests postmenopausal women using hormone therapy will experience more frequent, longer-lasting migraines. Results of the study were presented at the 2026 Annual Meeting of The Menopause Society in San Diego Oct. 20–24, 2026.
❓ Unknown
Hormone Therapy Linked to Increased Migraine Burden in Postmenopausal Women
2w ago
October 20, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
A study presented at The Menopause Society's Annual Meeting indicates that postmenopausal women using hormone therapy may experience increased frequency and duration of migraines. This finding is significant as it highlights health concerns that could affect women's quality of life in Iran, where access to healthcare and hormone therapy may vary. Understanding these health implications is crucial for women's health policies.
🔍 Quick Context Guide
💡 Bottom Line:
The study highlights potential risks of hormone therapy for postmenopausal women, emphasizing the need for careful consideration in treatment plans.
👥 Key Players
The Menopause Society
MENTIONED
Professional organization focused on menopause research and education
"They provide critical insights and research findings that influence women's health policies and practices, including in Iran."
Postmenopausal women
MENTIONED
Demographic affected by hormone therapy and migraines
"Their health outcomes are crucial for understanding the broader implications of hormone therapy in women's health."
📰 What Happened
A study presented at The Menopause Society's Annual Meeting indicates that postmenopausal women using hormone therapy may experience more frequent and longer-lasting migraines. This finding raises concerns about the quality of life for these women.
- Migraines affect 10% to 29% of women during the menopause transition.
- The study suggests that hormone therapy may exacerbate migraine symptoms in postmenopausal women.
💡 Why It Matters
🇮🇷 For Iran: In Iran, where healthcare access and women's health issues are critical, this study could inform better health policies and practices regarding hormone therapy.
🌍 Regional: The findings may resonate with other countries in the region facing similar women's health challenges.
🌐 International: Internationally, this research could affect how hormone therapy is prescribed and monitored, impacting women's health globally.
📚 Background
Hormone therapy is commonly used to alleviate menopausal symptoms, but its effects on migraines have been under-researched. Understanding these implications is essential for improving women's health outcomes.
Menopause management
Women's health policies
📡 Source:
NEUTRAL
📊 Confidence:
70%
The findings are presented by a reputable medical society, indicating a focus on scientific research rather than political agendas.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Davoud Rokhbin Executed for Murder in Kashan Prison
Just now •
Ali Mokhtari Executed for Rape in Shahre Kord
22 min ago •
Iran's Security Chief Urges US to Accept Tehran's Seven Conditions
24 min ago •
US Evacuates Aircraft from UK Bases Amid Rising Threats from Iran
30 min ago •